LS Investment Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

LS Investment Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,651	Closed	-$83K	–	993
2020 Q2	$83K	Hold	1,651	–	–	0.01%	1041
2020 Q1	$85K	Hold	1,651	–	–	0.01%	950
2019 Q4	$102K	Buy	1,651 +1,123	+213%	+$69.6K	0.01%	1109
2019 Q3	$32K	Hold	528	–	–	﹤0.01%	1419
2019 Q2	$45K	Hold	528	–	–	﹤0.01%	1336
2019 Q1	$50K	Hold	528	–	–	﹤0.01%	1299
2018 Q4	$37K	Sell	528 -2,458	-82%	-$188K	﹤0.01%	1348
2018 Q3	$255K	Sell	2,986 -678	-19%	-$67.9K	0.01%	742
2018 Q2	$425K	Buy	3,664 +34	+0.9%	+$3.39K	0.03%	566
2018 Q1	$294K	Sell	3,630 -84	-2%	-$6.46K	0.02%	692
2017 Q4	$218K	Buy	3,714 +1,345	+57%	+$67.3K	0.01%	849
2017 Q3	$111K	Buy	2,369 +561	+31%	+$22.6K	0.01%	1123
2017 Q2	$65K	Hold	1,808	–	–	﹤0.01%	1273
2017 Q1	$56K	Buy	1,808 +1,325	+274%	+$41.3K	﹤0.01%	1297
2016 Q4	$16K	Hold	483	–	–	﹤0.01%	1605
2016 Q3	$13K	Hold	483	–	–	﹤0.01%	1619
2016 Q2	$11K	Hold	483	–	–	﹤0.01%	1631
2016 Q1	$14K	Hold	483	–	–	﹤0.01%	1566
2015 Q4	$16K	Hold	483	–	–	﹤0.01%	1546
2015 Q3	$17K	Buy	+483	New	+$20.7K	﹤0.01%	1522

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LS Investment Advisors's ENTA Position: Q3 2020 in Review

LS Investment Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 1,651 shares — an estimated $83K sold.

LS Investment Advisors first reported a position in ENTA in Q3 2015 and held it in 20 quarters. The position peaked at $425K in Q2 2018. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

LS Investment Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
LS Investment Advisors sold 1,651 Enanta Pharmaceuticals shares in Q3 2020, an estimated $83K.
LS Investment Advisors first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 20 quarters.
LS Investment Advisors's Enanta Pharmaceuticals position peaked at $425K in Q2 2018.
172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on LS Investment Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.